NeoImmuneTech Starts Dosing in Phase 1 Clinical Trial of Immune Checkpoint Inhibitor 'NT-I7' Combination Therapy

[Asia Economy Reporter Chunhee Lee] NeoImmuneTech announced on the 6th that it has completed the first patient dosing in a combination clinical trial of its next-generation immune oncology drug 'NT-I7,' which induces T-cell expansion, and Novartis' 'Kymriah.'

This clinical trial is a multicenter Phase 1b study targeting patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It aims to evaluate safety, tolerability, and anticancer effects, and subsequently determine the recommended Phase 2 dose (RP2D).

DLBCL, a malignant lymphoma accounting for approximately 25-30% of non-Hodgkin lymphomas, is the most common subtype but still lacks a definitive curative treatment. In the United States alone, more than 20,000 patients are diagnosed annually, and about half of them experience side effects, relapse, or no response to treatment, making it one of the representative intractable diseases.

Yang Se-hwan, CEO of NeoImmuneTech, stated, “In various hematologic cancer animal models, we confirmed that when NT-I7 is administered together with CAR-T cell therapy, CAR-T cells significantly increase, and persistence and targeted therapy are greatly enhanced.” He added, “Through this combination clinical trial, we hope to extend the duration of response to Kymriah, improve overall response rates and survival, and provide patients with a breakthrough treatment option as soon as possible.”

This content was produced with the assistance of AI translation services.